Screening for depression in patients with epilepsy: What are the benefits for physicians and patients in the real‐life setting
Objective Screening for depression in people with epilepsy (PWE) is highly recommended in order to avoid underdiagnosis, misdiagnosis, or delayed diagnosis of this highly impacting comorbidity. Here we evaluated the impact of reporting and suggesting depression via the Beck Depression Inventory (BDI...
Gespeichert in:
Veröffentlicht in: | Epilepsia (Copenhagen) 2024-10, Vol.65 (10), p.3076-3082 |
---|---|
Hauptverfasser: | , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 3082 |
---|---|
container_issue | 10 |
container_start_page | 3076 |
container_title | Epilepsia (Copenhagen) |
container_volume | 65 |
creator | Wrede, Randi Witt, Juri‐Alexander Jessen, Nina Lossius, Morten I. Moskau‐Hartmann, Susanna Helmstaedter, Christoph |
description | Objective
Screening for depression in people with epilepsy (PWE) is highly recommended in order to avoid underdiagnosis, misdiagnosis, or delayed diagnosis of this highly impacting comorbidity. Here we evaluated the impact of reporting and suggesting depression via the Beck Depression Inventory (BDI) on medical decision‐making, and thereby the value of a depression screening for good medical practice.
Methods
Of 445 BDI data sets, PWE with scores indicating moderate (BDI 19–29) to severe depressive disorder (BDI >29) were extracted and clinical reports were retrospectively reviewed regarding decisions on antidepressants, anti‐seizure medications (ASMs), and non‐pharmaceutical interventions.
Results
Sixty‐four PWE (14%; 56% female; mean age 39.7 years) showed elevated BDI scores, with 40 (63%) categorized as moderate depression and 24 (37%) as severe depression. Thirty‐nine percent of PWE already had a pre‐existing diagnosis of depression and 53% left the clinic with the diagnosis of depression, half of them with antidepressants. High depression scores were associated with any intervention in 53%, interventions with potentially mood affecting ASM in 19%, treatment with antidepressants in 11%, and non‐pharmaceutical interventions in 41%. Non‐pharmaceutical interventions were related to BDI scores. Changes of potentially mood‐affecting ASMs were more frequent in PWE with moderate scores, and introduction of antidepressants appeared as a trend related to higher depression scores.
Significance
The finding of an only weak relation between high depression scores, diagnoses of depression, and treatment consequences questions the diagnosis and treatment pathway and the clinical value of the BDI screening in PWE. Prospective standard procedures need to be established for depression diagnosis and treatment including follow‐up evaluations of the validity of the diagnosis and effectiveness of the decisions taken. |
doi_str_mv | 10.1111/epi.18089 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3092871343</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3118986851</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3489-7b7394f31443e87ce519a68be0fe07bd51198fcc9d9b2e24d795e6beb8c736bd3</originalsourceid><addsrcrecordid>eNp1kcFO3DAQhq2KqizQQ18AWeJCDwFPnMQ2N4QoRUKiUkEcLduZsEZZJ7WzQnvjEfqMPEm9XUolJOYyl2--Gc1PyBdgR5DrGEd_BJJJ9YHMoC5lAdCILTJjDHihasm2yU5KD4wx0Qj-iWxzBRVTspyRp58uIgYf7mk3RNriGDElPwTqAx3N5DFMiT76aU7zlh7HtDqhd3MzURORTnOkFgN2PkPr-XG-St55ExI1of0vyLI1G9H0z0-_e98hTThNee0e-diZPuHnl75Lbr-d35x9L66uLy7PTq8KxyupCmEFV1XHoao4SuGwBmUaaZF1yIRtawAlO-dUq2yJZdUKVWNj0UoneGNbvksON94xDr-WmCa98Mlh35uAwzJpzlQpBfCKZ_TgDfowLGPI12kOIJVsZA2Z-rqhXBxSitjpMfqFiSsNTK9j0flh-m8smd1_MS7tAttX8l8OGTjeAI_5x6v3Tfr8x-VG-Qf2U5k0</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3118986851</pqid></control><display><type>article</type><title>Screening for depression in patients with epilepsy: What are the benefits for physicians and patients in the real‐life setting</title><source>Wiley Online Library Journals Frontfile Complete</source><creator>Wrede, Randi ; Witt, Juri‐Alexander ; Jessen, Nina ; Lossius, Morten I. ; Moskau‐Hartmann, Susanna ; Helmstaedter, Christoph</creator><creatorcontrib>Wrede, Randi ; Witt, Juri‐Alexander ; Jessen, Nina ; Lossius, Morten I. ; Moskau‐Hartmann, Susanna ; Helmstaedter, Christoph</creatorcontrib><description>Objective
Screening for depression in people with epilepsy (PWE) is highly recommended in order to avoid underdiagnosis, misdiagnosis, or delayed diagnosis of this highly impacting comorbidity. Here we evaluated the impact of reporting and suggesting depression via the Beck Depression Inventory (BDI) on medical decision‐making, and thereby the value of a depression screening for good medical practice.
Methods
Of 445 BDI data sets, PWE with scores indicating moderate (BDI 19–29) to severe depressive disorder (BDI >29) were extracted and clinical reports were retrospectively reviewed regarding decisions on antidepressants, anti‐seizure medications (ASMs), and non‐pharmaceutical interventions.
Results
Sixty‐four PWE (14%; 56% female; mean age 39.7 years) showed elevated BDI scores, with 40 (63%) categorized as moderate depression and 24 (37%) as severe depression. Thirty‐nine percent of PWE already had a pre‐existing diagnosis of depression and 53% left the clinic with the diagnosis of depression, half of them with antidepressants. High depression scores were associated with any intervention in 53%, interventions with potentially mood affecting ASM in 19%, treatment with antidepressants in 11%, and non‐pharmaceutical interventions in 41%. Non‐pharmaceutical interventions were related to BDI scores. Changes of potentially mood‐affecting ASMs were more frequent in PWE with moderate scores, and introduction of antidepressants appeared as a trend related to higher depression scores.
Significance
The finding of an only weak relation between high depression scores, diagnoses of depression, and treatment consequences questions the diagnosis and treatment pathway and the clinical value of the BDI screening in PWE. Prospective standard procedures need to be established for depression diagnosis and treatment including follow‐up evaluations of the validity of the diagnosis and effectiveness of the decisions taken.</description><identifier>ISSN: 0013-9580</identifier><identifier>ISSN: 1528-1167</identifier><identifier>EISSN: 1528-1167</identifier><identifier>DOI: 10.1111/epi.18089</identifier><identifier>PMID: 39140982</identifier><language>eng</language><publisher>United States: Wiley Subscription Services, Inc</publisher><subject>Antidepressants ; Beck Depression Inventory ; clinial decision‐making ; Comorbidity ; Decision making ; Diagnosis ; Epilepsy ; Medical diagnosis ; Medical screening ; Mental depression ; Mood ; Patients ; Pharmaceuticals ; screening for depression ; Seizures</subject><ispartof>Epilepsia (Copenhagen), 2024-10, Vol.65 (10), p.3076-3082</ispartof><rights>2024 The Author(s). published by Wiley Periodicals LLC on behalf of International League Against Epilepsy.</rights><rights>2024 The Author(s). Epilepsia published by Wiley Periodicals LLC on behalf of International League Against Epilepsy.</rights><rights>2024. This article is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c3489-7b7394f31443e87ce519a68be0fe07bd51198fcc9d9b2e24d795e6beb8c736bd3</cites><orcidid>0000-0002-6608-6244 ; 0000-0002-9430-5037</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fepi.18089$$EPDF$$P50$$Gwiley$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fepi.18089$$EHTML$$P50$$Gwiley$$Hfree_for_read</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39140982$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Wrede, Randi</creatorcontrib><creatorcontrib>Witt, Juri‐Alexander</creatorcontrib><creatorcontrib>Jessen, Nina</creatorcontrib><creatorcontrib>Lossius, Morten I.</creatorcontrib><creatorcontrib>Moskau‐Hartmann, Susanna</creatorcontrib><creatorcontrib>Helmstaedter, Christoph</creatorcontrib><title>Screening for depression in patients with epilepsy: What are the benefits for physicians and patients in the real‐life setting</title><title>Epilepsia (Copenhagen)</title><addtitle>Epilepsia</addtitle><description>Objective
Screening for depression in people with epilepsy (PWE) is highly recommended in order to avoid underdiagnosis, misdiagnosis, or delayed diagnosis of this highly impacting comorbidity. Here we evaluated the impact of reporting and suggesting depression via the Beck Depression Inventory (BDI) on medical decision‐making, and thereby the value of a depression screening for good medical practice.
Methods
Of 445 BDI data sets, PWE with scores indicating moderate (BDI 19–29) to severe depressive disorder (BDI >29) were extracted and clinical reports were retrospectively reviewed regarding decisions on antidepressants, anti‐seizure medications (ASMs), and non‐pharmaceutical interventions.
Results
Sixty‐four PWE (14%; 56% female; mean age 39.7 years) showed elevated BDI scores, with 40 (63%) categorized as moderate depression and 24 (37%) as severe depression. Thirty‐nine percent of PWE already had a pre‐existing diagnosis of depression and 53% left the clinic with the diagnosis of depression, half of them with antidepressants. High depression scores were associated with any intervention in 53%, interventions with potentially mood affecting ASM in 19%, treatment with antidepressants in 11%, and non‐pharmaceutical interventions in 41%. Non‐pharmaceutical interventions were related to BDI scores. Changes of potentially mood‐affecting ASMs were more frequent in PWE with moderate scores, and introduction of antidepressants appeared as a trend related to higher depression scores.
Significance
The finding of an only weak relation between high depression scores, diagnoses of depression, and treatment consequences questions the diagnosis and treatment pathway and the clinical value of the BDI screening in PWE. Prospective standard procedures need to be established for depression diagnosis and treatment including follow‐up evaluations of the validity of the diagnosis and effectiveness of the decisions taken.</description><subject>Antidepressants</subject><subject>Beck Depression Inventory</subject><subject>clinial decision‐making</subject><subject>Comorbidity</subject><subject>Decision making</subject><subject>Diagnosis</subject><subject>Epilepsy</subject><subject>Medical diagnosis</subject><subject>Medical screening</subject><subject>Mental depression</subject><subject>Mood</subject><subject>Patients</subject><subject>Pharmaceuticals</subject><subject>screening for depression</subject><subject>Seizures</subject><issn>0013-9580</issn><issn>1528-1167</issn><issn>1528-1167</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><recordid>eNp1kcFO3DAQhq2KqizQQ18AWeJCDwFPnMQ2N4QoRUKiUkEcLduZsEZZJ7WzQnvjEfqMPEm9XUolJOYyl2--Gc1PyBdgR5DrGEd_BJJJ9YHMoC5lAdCILTJjDHihasm2yU5KD4wx0Qj-iWxzBRVTspyRp58uIgYf7mk3RNriGDElPwTqAx3N5DFMiT76aU7zlh7HtDqhd3MzURORTnOkFgN2PkPr-XG-St55ExI1of0vyLI1G9H0z0-_e98hTThNee0e-diZPuHnl75Lbr-d35x9L66uLy7PTq8KxyupCmEFV1XHoao4SuGwBmUaaZF1yIRtawAlO-dUq2yJZdUKVWNj0UoneGNbvksON94xDr-WmCa98Mlh35uAwzJpzlQpBfCKZ_TgDfowLGPI12kOIJVsZA2Z-rqhXBxSitjpMfqFiSsNTK9j0flh-m8smd1_MS7tAttX8l8OGTjeAI_5x6v3Tfr8x-VG-Qf2U5k0</recordid><startdate>202410</startdate><enddate>202410</enddate><creator>Wrede, Randi</creator><creator>Witt, Juri‐Alexander</creator><creator>Jessen, Nina</creator><creator>Lossius, Morten I.</creator><creator>Moskau‐Hartmann, Susanna</creator><creator>Helmstaedter, Christoph</creator><general>Wiley Subscription Services, Inc</general><scope>24P</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-6608-6244</orcidid><orcidid>https://orcid.org/0000-0002-9430-5037</orcidid></search><sort><creationdate>202410</creationdate><title>Screening for depression in patients with epilepsy: What are the benefits for physicians and patients in the real‐life setting</title><author>Wrede, Randi ; Witt, Juri‐Alexander ; Jessen, Nina ; Lossius, Morten I. ; Moskau‐Hartmann, Susanna ; Helmstaedter, Christoph</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3489-7b7394f31443e87ce519a68be0fe07bd51198fcc9d9b2e24d795e6beb8c736bd3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Antidepressants</topic><topic>Beck Depression Inventory</topic><topic>clinial decision‐making</topic><topic>Comorbidity</topic><topic>Decision making</topic><topic>Diagnosis</topic><topic>Epilepsy</topic><topic>Medical diagnosis</topic><topic>Medical screening</topic><topic>Mental depression</topic><topic>Mood</topic><topic>Patients</topic><topic>Pharmaceuticals</topic><topic>screening for depression</topic><topic>Seizures</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wrede, Randi</creatorcontrib><creatorcontrib>Witt, Juri‐Alexander</creatorcontrib><creatorcontrib>Jessen, Nina</creatorcontrib><creatorcontrib>Lossius, Morten I.</creatorcontrib><creatorcontrib>Moskau‐Hartmann, Susanna</creatorcontrib><creatorcontrib>Helmstaedter, Christoph</creatorcontrib><collection>Wiley Online Library Open Access</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Epilepsia (Copenhagen)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wrede, Randi</au><au>Witt, Juri‐Alexander</au><au>Jessen, Nina</au><au>Lossius, Morten I.</au><au>Moskau‐Hartmann, Susanna</au><au>Helmstaedter, Christoph</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Screening for depression in patients with epilepsy: What are the benefits for physicians and patients in the real‐life setting</atitle><jtitle>Epilepsia (Copenhagen)</jtitle><addtitle>Epilepsia</addtitle><date>2024-10</date><risdate>2024</risdate><volume>65</volume><issue>10</issue><spage>3076</spage><epage>3082</epage><pages>3076-3082</pages><issn>0013-9580</issn><issn>1528-1167</issn><eissn>1528-1167</eissn><abstract>Objective
Screening for depression in people with epilepsy (PWE) is highly recommended in order to avoid underdiagnosis, misdiagnosis, or delayed diagnosis of this highly impacting comorbidity. Here we evaluated the impact of reporting and suggesting depression via the Beck Depression Inventory (BDI) on medical decision‐making, and thereby the value of a depression screening for good medical practice.
Methods
Of 445 BDI data sets, PWE with scores indicating moderate (BDI 19–29) to severe depressive disorder (BDI >29) were extracted and clinical reports were retrospectively reviewed regarding decisions on antidepressants, anti‐seizure medications (ASMs), and non‐pharmaceutical interventions.
Results
Sixty‐four PWE (14%; 56% female; mean age 39.7 years) showed elevated BDI scores, with 40 (63%) categorized as moderate depression and 24 (37%) as severe depression. Thirty‐nine percent of PWE already had a pre‐existing diagnosis of depression and 53% left the clinic with the diagnosis of depression, half of them with antidepressants. High depression scores were associated with any intervention in 53%, interventions with potentially mood affecting ASM in 19%, treatment with antidepressants in 11%, and non‐pharmaceutical interventions in 41%. Non‐pharmaceutical interventions were related to BDI scores. Changes of potentially mood‐affecting ASMs were more frequent in PWE with moderate scores, and introduction of antidepressants appeared as a trend related to higher depression scores.
Significance
The finding of an only weak relation between high depression scores, diagnoses of depression, and treatment consequences questions the diagnosis and treatment pathway and the clinical value of the BDI screening in PWE. Prospective standard procedures need to be established for depression diagnosis and treatment including follow‐up evaluations of the validity of the diagnosis and effectiveness of the decisions taken.</abstract><cop>United States</cop><pub>Wiley Subscription Services, Inc</pub><pmid>39140982</pmid><doi>10.1111/epi.18089</doi><tpages>7</tpages><orcidid>https://orcid.org/0000-0002-6608-6244</orcidid><orcidid>https://orcid.org/0000-0002-9430-5037</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0013-9580 |
ispartof | Epilepsia (Copenhagen), 2024-10, Vol.65 (10), p.3076-3082 |
issn | 0013-9580 1528-1167 1528-1167 |
language | eng |
recordid | cdi_proquest_miscellaneous_3092871343 |
source | Wiley Online Library Journals Frontfile Complete |
subjects | Antidepressants Beck Depression Inventory clinial decision‐making Comorbidity Decision making Diagnosis Epilepsy Medical diagnosis Medical screening Mental depression Mood Patients Pharmaceuticals screening for depression Seizures |
title | Screening for depression in patients with epilepsy: What are the benefits for physicians and patients in the real‐life setting |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-15T16%3A46%3A26IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Screening%20for%20depression%20in%20patients%20with%20epilepsy:%20What%20are%20the%20benefits%20for%20physicians%20and%20patients%20in%20the%20real%E2%80%90life%20setting&rft.jtitle=Epilepsia%20(Copenhagen)&rft.au=Wrede,%20Randi&rft.date=2024-10&rft.volume=65&rft.issue=10&rft.spage=3076&rft.epage=3082&rft.pages=3076-3082&rft.issn=0013-9580&rft.eissn=1528-1167&rft_id=info:doi/10.1111/epi.18089&rft_dat=%3Cproquest_cross%3E3118986851%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3118986851&rft_id=info:pmid/39140982&rfr_iscdi=true |